Cargando…

Alectinib (CH5424802) antagonizes ABCB1- and ABCG2-mediated multidrug resistance in vitro, in vivo and ex vivo

Alectinib, an inhibitor of anaplastic lymphoma kinase (ALK), was approved by the Food and Drug Administration (FDA) for the treatment of patients with ALK-positive non-small cell lung cancer (NSCLC). Here we investigated the reversal effect of alectinib on multidrug resistance (MDR) induced by ATP-b...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yang, Ke, Chen, Yifan, To, Kenneth Kin Wah, Wang, Fang, Li, Delan, Chen, Likun, Fu, Liwu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2017
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5382559/ https://www.ncbi.nlm.nih.gov/pubmed/28303028 http://dx.doi.org/10.1038/emm.2016.168

Ejemplares similares

Correction: Alectinib (CH5424802) antagonizes ABCB1- and ABCG2-mediated multidrug resistance in vitro, in vivo and ex vivo
por: Yang, Ke, et al.
Publicado: (2020)

Lazertinib improves the efficacy of chemotherapeutic drugs in ABCB1 or ABCG2 overexpression cancer cells in vitro, in vivo, and ex vivo
por: Fan, Yingfang, et al.
Publicado: (2022)

Reversal of ABCB1-related multidrug resistance by ERK5-IN-1
por: Wang, Fang, et al.
Publicado: (2020)

Reversal effect of FW-04-806, a macrolide dilactone compound, on multidrug resistance mediated by ABCB1 and ABCG2 in vitro and in vivo
por: Zhang, Zhiqiang, et al.
Publicado: (2019)

Adagrasib, a KRAS G12C inhibitor, reverses the multidrug resistance mediated by ABCB1 in vitro and in vivo
por: Zhang, Yuchen, et al.
Publicado: (2022)

Phase II trial of CH5424802 (alectinib hydrochloride) for recurrent or refractory ALK-positive anaplastic large cell lymphoma: study protocol for a non-randomized non-controlled trial
por: Nagai, Hirokazu, et al.
Publicado: (2017)

MET inhibitor tepotinib antagonizes multidrug resistance mediated by ABCG2 transporter: In vitro and in vivo study
por: Wu, Zhuo-Xun, et al.
Publicado: (2022)

Effect of ceritinib (LDK378) on enhancement of chemotherapeutic agents in ABCB1 and ABCG2 overexpressing cells in vitro and in vivo
por: Hu, Jing, et al.
Publicado: (2015)

VS-4718 Antagonizes Multidrug Resistance in ABCB1- and ABCG2-Overexpressing Cancer Cells by Inhibiting the Efflux Function of ABC Transporters
por: Ji, Ning, et al.
Publicado: (2018)

Talazoparib Does Not Interact with ABCB1 Transporter or Cytochrome P450s, but Modulates Multidrug Resistance Mediated by ABCC1 and ABCG2: An in Vitro and Ex Vivo Study
por: Sabet, Ziba, et al.
Publicado: (2022)

Rociletinib (CO-1686) enhanced the efficacy of chemotherapeutic agents in ABCG2-overexpressing cancer cells in vitro and in vivo
por: Zeng, Fanpu, et al.
Publicado: (2020)

Thiazole-valine peptidomimetic (TTT-28) antagonizes multidrug resistance in vitro and in vivo by selectively inhibiting the efflux activity of ABCB1
por: Wang, Yi-Jun, et al.
Publicado: (2017)

Icotinib antagonizes ABCG2-mediated multidrug resistance, but not the pemetrexed resistance mediated by thymidylate synthase and ABCG2
por: Wang, De-Shen, et al.
Publicado: (2014)

Erdafitinib Antagonizes ABCB1-Mediated Multidrug Resistance in Cancer Cells
por: Feng, Weiguo, et al.
Publicado: (2020)

Vandetanib (Zactima, ZD6474) Antagonizes ABCC1- and ABCG2-Mediated Multidrug Resistance by Inhibition of Their Transport Function
por: Zheng, Li-sheng, et al.
Publicado: (2009)

VKNG-1 Antagonizes ABCG2-Mediated Multidrug Resistance via p-AKT and Bcl-2 Pathway in Colon Cancer: In Vitro and In Vivo Study
por: Narayanan, Silpa, et al.
Publicado: (2021)

Bafetinib (INNO-406) reverses multidrug resistance by inhibiting the efflux function of ABCB1 and ABCG2 transporters
por: Zhang, Yun-Kai, et al.
Publicado: (2016)

Polyoxypregnanes as safe, potent, and specific ABCB1-inhibitory pro-drugs to overcome multidrug resistance in cancer chemotherapy in vitro and in vivo
por: Wu, Xu, et al.
Publicado: (2021)

Sitravatinib Sensitizes ABCB1- and ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs
por: Wu, Chung-Pu, et al.
Publicado: (2020)

Poziotinib Inhibits the Efflux Activity of the ABCB1 and ABCG2 Transporters and the Expression of the ABCG2 Transporter Protein in Multidrug Resistant Colon Cancer Cells
por: Zhang, Yongchao, et al.
Publicado: (2020)

Quizartinib (AC220) reverses ABCG2-mediated multidrug resistance: In vitro and in vivo studies
por: Li, Jun, et al.
Publicado: (2017)

A Phenylfurocoumarin Derivative Reverses ABCG2-Mediated Multidrug Resistance In Vitro and In Vivo
por: Kokubo, Shoji, et al.
Publicado: (2021)

The Characterization of chIFITMs in Avian Coronavirus Infection In Vivo, Ex Vivo and In Vitro
por: Steyn, Angela, et al.
Publicado: (2020)

Characterisation of the roles of ABCB1, ABCC1, ABCC2 and ABCG2 in the transport and pharmacokinetics of actinomycin D in vitro and in vivo
por: Hill, Christopher R., et al.
Publicado: (2013)

Imperatorin Restores Chemosensitivity of Multidrug-Resistant Cancer Cells by Antagonizing ABCG2-Mediated Drug Transport
por: Wu, Chung-Pu, et al.
Publicado: (2023)

Cetuximab enhanced the efficacy of chemotherapeutic agent in ABCB1/P-glycoprotein-overexpressing cancer cells
por: Wang, Fang, et al.
Publicado: (2015)

A new fluorescent dye accumulation assay for parallel measurements of the ABCG2, ABCB1 and ABCC1 multidrug transporter functions
por: Szabó, Edit, et al.
Publicado: (2018)

Ginsenoside Rg5 overcomes chemotherapeutic multidrug resistance mediated by ABCB1 transporter: in vitro and in vivo study
por: Feng, Sen-Ling, et al.
Publicado: (2020)

Dacomitinib potentiates the efficacy of conventional chemotherapeutic agents via inhibiting the drug efflux function of ABCG2 in vitro and in vivo
por: Guo, Xiaoran, et al.
Publicado: (2018)

Down-regulation of ABCG2 and ABCB4 transporters in the placenta of rats exposed to cadmium
por: Liu, Lili, et al.
Publicado: (2016)

ABCB1 and ABCG2 Together Limit the Distribution of ABCB1/ABCG2 Substrates to the Human Retina and the ABCG2 Single Nucleotide Polymorphism Q141K (c.421C> A) May Lead to Increased Drug Exposure
por: El Biali, Myriam, et al.
Publicado: (2021)

ABCG2-overexpressing H460/MX20 cell xenografts in athymic nude mice maintained original biochemical and cytological characteristics
por: Zhang, Wei, et al.
Publicado: (2017)

In vitro and ex vivo anti-tumor effect and mechanism of Tucatinib in leukemia stem cells and ABCG2-overexpressing leukemia cells
por: Jing, Wen, et al.
Publicado: (2021)

Dual TTK/CLK2 inhibitor, CC‐671, selectively antagonizes ABCG2‐mediated multidrug resistance in lung cancer cells
por: Wu, Zhuo‐Xun, et al.
Publicado: (2020)

Improved Brain Penetration and Antitumor Efficacy of Temozolomide by Inhibition of ABCB1 and ABCG2()
por: de Gooijer, Mark C., et al.
Publicado: (2018)

Author Correction: ABCG2-overexpressing H460/MX20 cell xenografts in athymic nude mice maintained original biochemical and cytological characteristics
por: Zhang, Wei, et al.
Publicado: (2020)

Furmonertinib, a Third-Generation EGFR Tyrosine Kinase Inhibitor, Overcomes Multidrug Resistance through Inhibiting ABCB1 and ABCG2 in Cancer Cells
por: Wu, Chung-Pu, et al.
Publicado: (2023)

CH02 peptide promotes ex vivo expansion of umbilical cord blood-derived CD34 (+) hematopoietic stem/progenitor cells : CH02 peptide promotes CD34 (+) UCB-HSPC ex vivo expansion
por: Yang, Yiqi, et al.
Publicado: (2023)

ABCG1 maintains high-grade glioma survival in vitro and in vivo
por: Chen, Yi-Hsien, et al.
Publicado: (2016)

Ex Vivo Lung Perfusion with K(ATP) Channel Modulators Antagonize Ischemia Reperfusion Injury
por: Arni, Stephan, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_4q4krdposg4iej53k4vj6gubpo